# A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban

> **NCT02213029** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 33 (actual)

## Conditions studied

- Embryo Transfer

## Interventions

- **DRUG:** Epelsiban
- **DRUG:** Placebo
- **DRUG:** Oxytocin
- **DRUG:** Ortho-Cylcen (21)® tablet

## Key facts

- **NCT ID:** NCT02213029
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08-28
- **Primary completion:** 2016-02-07
- **Final completion:** 2016-02-07
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02213029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02213029, "A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02213029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*